Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2376 - 2400 of 14971 in total

Streptomycin

Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic...
Approved
Vet approved
Matched Description: … Medicine for their discovery of streptomycin and its antibacterial activity. ... [A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in ... Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and …
Matched Categories: … Alimentary Tract and Metabolism ... streptomycin and isoniazid …

Fosnetupitant

In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form...
Approved
Matched Description: … Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation ... of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) ... as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting …
Matched Categories: … Netupitant and prodrug …

Aducanumab

Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to gantenerumab, bapineuzumab and solanezumab.[A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a...
Approved
Investigational
Matched Description: … that targets extracellular amyloid-β plaques in the brain; similar to [gantenerumab], [bapineuzumab] and ... ] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and ... [A235668] Based on Mini-Mental State Examination and Clinical Dementia Rating (CDR), patients taking …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Granisetron

A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Approved
Investigational
Matched Description: … A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant …
Matched Categories: … Alimentary Tract and Metabolism ... Antiemetics and Antinauseants …

Flucytosine

A fluorinated cytosine analog that is used as an antifungal agent.
Approved
Investigational
Matched Categories: … Fluorouracil and prodrugs …

Ergoloid mesylate

Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. All these components are produced by the fungus Claviceps purpurea and are all derivatives of the tetracyclic compound 6-methylergonovine. The derivatives of this fungus are identified to be about 350 different substances from which the components...
Approved
Matched Description: … [A32912] All these components are produced by the fungus _Claviceps purpurea_ and are all derivatives ... equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and ... [A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November …
Matched Categories: … Ergot Alkaloids and Derivatives …

Mepolizumab

Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically defined as absolute eosinophil levels of 1500/mm3 or more) is associated with a spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). The pathogenesis of eosinophilia is complex, but IL-5 is recognized as...
Approved
Investigational
Matched Description: … Activated eosinophils further stimulate an inflammatory response and also induce tissue lesions and promote ... Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically ... spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Evinacumab

Evinacumab is a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and the first drug of its kind. The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in...
Approved
Investigational
Matched Description: … [L31838] In September and December 2023, evinacumab was also approved by Health Canada and EMA, respectively ... provides a unique and synergistic therapeutic option in the treatment of HoFH. ... a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Gimeracil

Gimeracil is an adjunct to antineoplastic therapy, used to increase the concentration and effect of the main active componets within chemotherapy regimens. Approved by the European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with DB03209 and DB09256 within the commercially available product "Teysuno". The main active...
Approved
Matched Description: … Gimeracil is an adjunct to antineoplastic therapy, used to increase the concentration and effect of the ... European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with [DB03209] and ... By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, …

Elexacaftor

Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It received FDA approval in October 2019 in combination with tezacaftor and ivacaftor as the combination product TrikaftaTM. Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure...
Approved
Investigational
Matched Description: … [A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as ... Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and ... to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and …
Matched Categories: … ivacaftor, tezacaftor and elexacaftor …

Thiabendazole

2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)
Approved
Vet approved
Matched Description: … It has CNS side effects and hepatototoxic potential. ... (From Smith and Reynard, Textbook of Pharmacology, 1992, p919) ... It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. …
Matched Categories: … Imidazole and Triazole Derivatives ... Antiparasitic Products, Insecticides and Repellents …

Tocainide

An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
Approved
Matched Description: … An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels. …

Hydrocortisone succinate

Approved
Matched Iupac: … 3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid …
Matched Categories: … Hydrocortisone and derivatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Erdafitinib

In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing...
Approved
Investigational
Matched Description: … for patients with metastatic bladder cancer, which demonstrates the development of more personalized and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Piritramide

Piritramide is under investigation for the treatment of Colon Cancer and Minimal Residual Disease. Piritramide has been investigated for the supportive care of Pain, Postoperative and Postoperative Nausea and Vomiting.
Approved
Investigational
Matched Description: … and Vomiting. ... Piritramide is under investigation for the treatment of Colon Cancer and Minimal Residual Disease. ... Piritramide has been investigated for the supportive care of Pain, Postoperative and Postoperative Nausea …

Trabectedin

Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair...
Approved
Investigational
Matched Description: … and ovarian cancer. ... and DNA repair machinery. ... Both the European Commission and the U.S. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Lumateperone

Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including aripiprazole, paliperidone and clozapine available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the...
Approved
Investigational
Matched Description: … Schizophrenia is a complex mental illness and impacts approximately 1% of the population. ... [L10902] Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine ... ] available for clinical use, they are generally accompanied by significant metabolic and/or neurological …

Aprocitentan

Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of macitentan. Approximately 10-15% of patients with hypertension have resistant hypertension, defined as uncontrolled high blood pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel blocker,...
Approved
Investigational
Matched Description: … [A263386] and have traditionally had limited additional treatment options. ... Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension ... pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel blocker, and …

Rucaparib

Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer...
Approved
Investigational
Matched Description: … Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. ... [L42185] It is currently used to treat recurrent ovarian and prostate cancer in adults. ... [A18745] Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Ropeginterferon alfa-2b

Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term propensity for myelofibrosis and leukemia.[A242000, A242005] Interferon alfa-2b has been used for decades to treat PV but requires frequent dosing...
Approved
Investigational
Matched Description: … and clinical trials. ... platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term ... propensity for myelofibrosis and leukemia. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Olutasidenib

Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022.[L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. IDH1 mutations are common in...
Approved
Investigational
Matched Description: … and gliomas (NCT03684811). ... Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved ... in different types of cancer, such as gliomas, AML, intrahepatic cholangiocarcinoma, chondrosarcoma, and …

5-O-phosphono-alpha-D-ribofuranosyl diphosphate

The key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides.
Approved
Experimental
Investigational
Matched Iupac: … ,3R,4S,5R)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]oxy}(hydroxy)phosphoryl)oxy]phosphonic acid …
Matched Description: … The key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides …

Hexylresorcinol

Hexylresorcinol is a substituted dihydroxybenzene. It exhibits antiseptic, anthelmintic, and local anesthetic properties. It can be found in topical applications for minor skin infections and in oral solutions or throat lozenges for pain relief and first aid antiseptic. The compound may also be used commonly in various commercial cosmetic anti-aging...
Approved
Matched Description: … for pain relief and first aid antiseptic. ... It exhibits antiseptic, anthelmintic, and local anesthetic properties. ... It can be found in topical applications for minor skin infections and in oral solutions or throat lozenges …

Trilaciclib

Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer. CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis...
Approved
Investigational
Matched Description: … and chemotherapy. ... Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy ... induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing …

Practolol

A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.
Approved
Displaying drugs 2376 - 2400 of 14971 in total